Respiratory physicians asked for their take on the possible pulmonary side effects of small molecule tyrosine kinase inhibitors (TKIs) can reassure their colleagues. According to a meta-analysis of all published trial data on adverse events, there is some signal for infections but none for an increased risk of pulmonary embolism (PE). The findings are timely, ...
Already a member?
Enter your email to keep reading.